Unlocking the Power of Prevention: Vaxcyte’s 24-Valent Vaccine Shows Promise in Adult Proof-of-Concept Study Published in The Lancet Infectious Diseases
Exploring the Exciting Potential of VAX-24 An In-Depth Look at the Phase 1/2 Adult Proof-of-Concept Data Introduction Recently, groundbreaking results from the Phase 1/2 study of VAX-24 were published in The Lancet Infectious Diseases, shedding light on the impressive safety, tolerability, and immunogenicity profile of this innovative vaccine. The data revealed that VAX-24 demonstrated a…